Evaluating lipid-based nanoparticle delivery of dsDNA agonists for activation of cGAS-STING pathway Kay Russi^{1*}, James Wang², Santiago Correa, Ph.D.² ¹Department of Bioengineering, Clemson University, Clemson, SC ²Department of Biomedical Engineering, Columbia University, New York, NY

INTRODUCTION

In eukaryotes, DNA is primarily found in the nucleus and mitochondria. The presence of cytosolic DNA is typically a sign of internal dysregulation or presence of pathogens.^[1] The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is responsible for detecting cytosolic DNA and eliciting an innate immune response to protect the cell.^[2] Activation of this pathway plays an important role in cancer immunotherapies.^[3] To activate this pathway, exogenous double-stranded DNA (dsDNA) must be delivered into the cytosol of a cell to stimulate cGAS. When cGAS detects dsDNA, cGAMP is produced, which activates STING. In response, type I interferons are produced, eliciting an immune response,



such as dendritic cell maturation, which can lead to more adoptive immune cell activity, and overcoming an immunosuppressive

tumor environment. This study looks to use lipidnanoparticles based (LBNPs) encapsulated with a dsDNA agonist to effectively safely and the cGASstimulate STING pathway.

References [1] Li, A. J Hematol Oncol (2019) [2] Oh, J. Royal Society of Chemistry (2020) [3] Motwani, M. Nat Rev Genet (2019

METHODS

- LNPs were synthesized via pipette mixing and each encapsulates G3YSD, a Y-form dsDNA agonist. Encapsulation efficiency assessed by Quant-iT RiboGreen **RNA** Assay
- Particle size and charge determined by dynamic light scattering (DLS)
- cGAS-STING pathway activation assessed in THP-1 reporter cell line for NFkB and IFN induction



800 600H Size (nm) 400-

150000[.]







SM102 LNPs



SM102 lipid.



James Wang.

Connect with me on LinkedIn!